• Anlotinib Hydrochloride: Evidence and Research Context

  2026-10-08

  An evidence-focused overview of Anlotinib hydrochloride as a multi-target tyrosine kinase inhibitor, covering anti-angiogenic mechanisms, reported laboratory findings, a rare-tumor case report, evidence strength, and applicability limits.

• Dual-Action Inhibitors and p38α Dephosphorylation

  2026-10-08

  A 2024 bioRxiv preprint reports that selected p38α MAP kinase inhibitors can do more than occupy the kinase active site: they can also increase WIP1-mediated dephosphorylation of the kinase activation loop. Structural and biochemical evidence links this effect to an inhibitor-stabilized activation-loop conformation, suggesting a route toward kinase inhibitors that influence both catalytic activity and signaling-state reset.

• Cefiderocol Activity in Resistant European Nonfermenters

  2026-10-07

  The ARTEMIS study compared cefiderocol with established and emerging β-lactam/β-lactamase inhibitor combinations across 1,451 European Pseudomonas aeruginosa and Acinetobacter spp. isolates. Its principal contribution is the large, geographically distributed in vitro dataset showing high cefiderocol susceptibility among meropenem-resistant and comparator-resistant non-fermenters, while also identifying genetic patterns associated with cefiderocol resistance.

• ICAA Disrupts HBV Replication via HO-1 and ROS

  2026-10-07

  The reference study identifies isochlorogenic acid A (ICAA) as a multitarget inhibitor of hepatitis B virus replication, linking HO-1 induction and reactive oxygen species modulation to effects on viral transcription, cccDNA, capsid formation, and envelopment. Its main contribution is mechanistic integration: rather than treating antiviral activity as a single replication endpoint, the study maps ICAA-associated changes across several stages of the HBV life cycle while defining the limits of cell-based evidence.

• Promethazine HCl in Host-Directed Immunity Research

  2026-10-06

  Promethazine HCl is a phenothiazine-derived histamine H1 antagonist used as a pharmacological research probe. A 2025 Frontiers in Immunology study reported that phenothiazines enhanced macrophage antibacterial activity alongside increased reactive oxygen species, lysosomal activity, and autophagy. However, the strongest in vivo evidence involved perphenazine rather than promethazine, so class-level findings should not be treated as proof of equivalent promethazine activity. This overview separates reported results from interpretation and defines the evidence, research applications, and limitations.

• Polybrene: Research Context and Evidence Limits

  2026-10-06

  Polybrene, also called Hexadimethrine Bromide, is a cationic polymer described as a viral gene transduction enhancer and a facilitator of nucleic-acid delivery. This overview separates supplier claims from study-level evidence, explains conceptual applications, and outlines limitations that restrict cross-cell-type and cross-assay interpretation.

• PLGA Nano-Adjuvant Boosts Chick Mucosal Immunity

  2026-10-05

  Muhetaer et al. report a PEI-modified PLGA nanoparticle adjuvant that co-delivers Lagenaria siceraria polysaccharide and retinoic acid in support of an inactivated H9N2 vaccine. In chicks, the formulation was associated with higher serum IgG and intestinal IgA, together with evidence of intestinal targeting involving CCR9- and CCR6-related chemokine pathways. The findings are promising preclinical evidence, but the supplied report does not establish protection against infection or transferability to other species.

• Anlotinib Hydrochloride: A Translational View

  2026-10-05

  A source-grounded perspective on how Anlotinib hydrochloride connects VEGFR2 biology with broader angiogenic signaling, and how translational teams can interpret the evidence without overstating preclinical promise.

• EMD638683 and the Mechanics of SGK1 Signaling

  2026-10-04

  Explore how EMD638683, an SGK1 inhibitor, can help interpret the relationship between SGK1 activity, endothelial mechanics, vascular stiffening, and downstream signaling. This evidence-centered guide distinguishes pharmacological target engagement from broader disease-model interpretation.

• Triacetin Digestion and Hepatic Metabolic Signaling

  2026-10-03

  A 2025 rapid communication in Lipids clarifies how the short-chain triacylglycerol triacetin is digested and absorbed in rats. The study links rapid upper-gastrointestinal breakdown to portal delivery of acetate and glycerol, with accompanying changes in hepatic AMPK signaling and lipid-metabolism gene expression.

• MCL-1 Dependence in Breast Cancer: Study Insights

  2026-10-01

  This study shows that MCL-1 sustains established breast tumors primarily through its canonical anti-apoptotic activity, rather than through an apoptosis-independent tumor-promoting function. Genetic deletion and pharmacological inhibition were both linked to BAX/BAK-dependent tumor control, providing a mechanistic rationale for evaluating MCL-1-directed BH3 mimetics in breast cancer research.

• Haloprogin: From MIC to Translational Strategy

  2026-10-01

  Haloprogin offers translational researchers more than a low-MIC topical antifungal profile. Its activity across dermatophytes, Candida, and selected Gram-positive bacteria, combined with unresolved target biology and formulation-dependent behavior, creates a useful framework for connecting phenotypic screening with clinically relevant topical models.

• Matrine Assay Workflows for Cancer Research

  2026-09-30

  Matrine supports a practical, multi-endpoint strategy for studying tumor viability, stemness, apoptosis, and inflammatory signaling. This guide translates thymoma findings into reproducible workflows while separating reported evidence from exploratory assay extensions.

• Cimetidine in BBB and Cancer Research

  2026-09-30

  Cimetidine can support two complementary research tracks: H2 receptor biology in gastrointestinal cancer models and mechanistic permeability testing in surrogate blood-brain barrier assays. This practical guide combines formulation advice, Transwell workflow design, P-glycoprotein analysis, and recovery-based troubleshooting without overstating what the reference model has validated.

• A-1210477: MCL-1 Inhibitor Workflow Guide

  2026-09-29

  Build a mechanism-first apoptosis workflow around A-1210477 to distinguish true MCL-1 dependence from nonspecific cytotoxicity. This guide covers compound handling, mitochondrial readouts, BAX/BAK validation, combination testing, and practical troubleshooting for cancer research.

8086 records 1/540 page Next 12345 下5页 Last page